Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 56 · Cited by 119
- Authors
- Fizazi, K., & Gillessen, S.
- Affiliations
- Université Paris-Saclay (FR)
- Istituto Oncologico della Svizzera Italiana (CH)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 34
- Issue
- 6
- Pages
- 557-563
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4328105394
- Cited by
- 119
- References
- 56
- Citations by year
- 2026: 22 · 2025: 61 · 2024: 32 · 2023: 4
- FWCI
- 21.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Society for Medical Oncology
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- prostate cancer, treatment guidelines, abiraterone, prednisone, androgen deprivation therapy, radiotherapy, metastatic hormone-sensitive prostate cancer, docetaxel, darolutamide, olaparib, BRCA mutations, cabazitaxel, metastatic castration-resistant prostate cancer, 177Lu-PSMA-617, taxanes
- MeSH terms
- Humans, Male, Prostatic Neoplasms, Treatment Outcome, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
